Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective
Abstract Background The cost-effectiveness of NALIRIFOX as a potential new standard of care for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) has yet to be established. Our objective was to evaluate the cost-effectiveness of NALIRIFOX vs. nab-paclitaxel and gemcitabine in this in...
Na minha lista:
| Principais autores: | , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BMC
2024-09-01
|
| Serier: | Cost Effectiveness and Resource Allocation |
| Fag: | |
| Online adgang: | https://doi.org/10.1186/s12962-024-00578-5 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|